Psoriasis in the era of biologics;Psoríase na era dos biológicos

Acta Medica Portuguesa

Volumn 23, Issue 3, 2010, Pages 493-498

  Torres, Tiago ^a   Velho, Glória Cunha ^a   Sanches, Madalena ^a   Selores, Manuela ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE;

DRUG EFFICACY; DRUG SAFETY; EUROPE; EUROPEAN UNION; IMMUNOPATHOGENESIS; PHOTOCHEMOTHERAPY; PSORIASIS VULGARIS; QUALITY OF LIFE; REVIEW;

BIOLOGICAL AGENTS; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958607845     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. VAN DE KERKHOF PC: Consistent control o psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006;20:639-650 (Pubitemid 43919124)
2. SMITH CH, ANSTEY AV, BARKER JN et al: British Association of Dermatologists guidelines for use of biological interventions in Psoriasis 2005;153:486-497
3. BAUGH JA, BUCALA R: Mechanisms for modulating TNF alpha in immune inflammatory disease. Curr Opin Drug Discov Dev 2001;4:635-650
4. JACKSON JM: TNF alpha inhibitors. Dermatol Therapy 2007;20:251-264
5. MEASE KB, LANGLEY RG, LEONARDI C et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
6. MEASE PJ, KIVITZ AJ, BURCH FX et al: Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004;50:2264-72
7. ANTONI C, KRUEGER GG, DE VLAM K et al: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
8. YAMAUCHI PS, GINDI V, LOWE NJ: The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy and safety. Dermatol Clin 2004;22:449-459
9. GISONDI P, GUBINELLI E, COCUROCCIA B, GIROLOMONI G: Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:175-183 (Pubitemid 38832748)
10. BISSONNETTE R: Etanercept for the treatment of psoriasis. Skin Therapy Lett 2006;11:1-4
11. WINTERFIELD L, MENTER A: Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 2004;22:437-447
12. MENTER A, GRIFFITHS CE: Current and future management of psoriasis. Lancet 2007;370:272-284
13. GORDON KB, LANGLEY RG, LEONARDI C et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind randomized controlled trial and open label extension study. J Am Acad Dermatol 2006;55:598-606
14. MERGOLIS D, BILDER W, NENNESSY S et al: The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-783
15. HAMILTON CD: Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004;16:392-8
16. KWON HJ, COTE TR, CUFE MS et al: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-811
17. CALABRESE LH, ZEIN N: Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 2007;3:422-3
18. SHEAR NH, LANGLEY RG, HO V: Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2006;9:4-9 (Pubitemid 44244079)
19. MENTER A, GORDON K, CAREY W et al: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8
20. FRETZIN S, CROWLEY J, JONES L, TOUNG M, SOBELL J: Successful treatment of hand and foot psoriasis with efalizumab therapy. J Drug Dermatol 2006;5:838-846
21. GOTTLIEB AB, HAMILTON T, CARO I et al: Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54:S154-S163
22. INFARMED: Circular Informativa no. 036/CD, de 19/02/2009
23. KRUEGER GG, LANGLEY RG, LEONARDI C et al: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
24. LEONARDI CL, KIMBALL AB, PAPP KA et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;317:1665-73